

Date of preparation: **2023-10-18**

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Update on the scope of services provided to Novavax, Inc. under SOW#8.

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 26/2022 of 2 August 2022 regarding the signing, with Novavax, Inc. ("Novavax"), of Statement of Work #8 ("SOW#8") as part of the Commercial Contract Manufacturing Agreement ("Manufacturing Agreement"), the Management Board of Mabion S.A. ("Company") hereby informs that on 18 October 2023, the parties agreed to terminate SOW#8.

In the agreement on the termination of SOW#8 ("Agreement"), the Company and Novavax have resolved to discontinue the tests conducted to date and to mutually release each other from all liabilities incurred prior to the effective date of the Agreement.

Under SOW#8, the Company carried out stability testing with regard to the active substance SARS CoV-2 rS – Wuhan variant, over a period of three years for each batch covered by the research. Novavax has informed that there is no need for the stability tests for the Wuhan variant to continue. Concurrently, stability testing of the active substance SARS CoV-2 rS – Omicron variant (carried out on the basis of Annex no. 2 to Statement of Work #1, as referred to in Current Report no. 5/2023 of 6 April 2023) is being continuously conducted. With the above in mind, the discontinuation of SOW#8 will not have any material impact on the Company's financial position or the extent of its collaboration with Novavax.

Other services under the Manufacturing Agreement and the Statements of Work are being provided as envisaged.